Our laboratory has previously shown that apelin is mitogenic for endothelial cells. We have postulated that apelin represents an angiogenic factor secreted by tumour cells in order to promote the formation of new vessels necessary for tumour growth. We first demonstrate that apelin and its receptor are not expressed by the mouse TS/A mammary carcinoma cells. We therefore established clones of this tumoral cell type stably overexpressing the apelin cDNA (TS/A-apelin clones). Comparison of the in vitro proliferation rates between TS/A-mock and TS/A-apelin cells did not reveal any difference and confirmed the lack of receptor expression by tumour cells. On the other hand, apelin overexpression clearly increased the in vivo tumour growth and this increase was associated with an earlier onset of tumour development. In tumours derived from TS/A-apelin clones, the expression of the endothelial marker CD31 was increased and revealed the formation of large intratumoral vessels lined with CD31 positive cells. These data suggest that apelin behaves as a potent activator of tumour neoangiogenesis by a paracrine effect on host vessels. The pathological relevance of this finding is demonstrated by hypoxiainduced upregulation of apelin gene and its overexpression in one-third of human tumours.
Introduction
The development of the vascular system is an early event in organogenesis that requires the participation of many signalling pathways. Integration of the signals decoded by different membrane receptors orchestrates the cellular events, which act at different stages from the formation of the primitive network by vasculogenesis to its remodelling into the arborescent vascular tree by angiogenesis (Coultas et al., 2005) .
The most intensively studied signalling pathway that drives angiogenesis utilizes vascular endothelial growth factor VEGF-A and its receptor VEGFR-2. Spatiotemporal expression of VEGF-A and the VEGFR-2 receptor is correlated with the early development of the vascular system (Breier et al., 1992; Millauer et al., 1993) . Knockout of each gene results in embryonic lethality that was characterized by a vascular-mutant phenotype in mice (Shalaby et al., 1995; Carmeliet et al., 1996; Ferrara et al., 1996) . Regardless of the cell type that produces VEGF-A, VEGFR-2 receptors expressed at the surface of endothelial cells are the major mediators of the mitogenic and angiogenic effects of this ligand (Ferrara, 2004) . As VEGF-A gene expression is upregulated by hypoxia (Shweiki et al., 1992) , this property provides a rational for its role in the adjustment of the vascular supply to the metabolic demand. Hypoxic tissues would therefore drive the formation of new vessels by the secretion of VEGF-A, which promotes angiogenesis through the migration and the proliferation of endothelial cells (Pugh and Ratcliffe, 2003) .
Many of these developmental events are recapitulated during neoangiogenesis in the adult. Physiological neovascularization induced after tissue damage or pathological neovascularization observed in tumour growth and ischaemic retinopathies also involve the formation or the recruitment of new vessels by the reactivation of VEGF-A/VEGFR-2 receptor signalling pathway (Ferrara and Kerbel, 2005) . Upregulation of VEGF-A gene expression by hypoxic regions inside tumours was first considered as the triggering event for the induction of tumour neoangiogenesis (Plate et al., 1993) . However, other data reveal that activation of various oncogenes (Rak et al., 1995) or inactivation of various tumour suppressor genes (Brugarolas and Kaelin, 2004) can also result in VEGF-A upregulation. Whatever the origin of VEGF-A upregulation, VEGF-A messenger RNA is highly expressed in many human tumours (Dvorak, 2002) .
Although the VEGF-A signalling pathway plays a prominent role in developmental angiogenesis and pathological neoangiogenesis, these processes clearly require the coordinated action of a variety of ligands and receptors. We have identified two orthologous genes, an amphibian gene (X-msr) and a murine gene (msr/apj), which encode G protein-coupled receptors and represent an early and unique marker for vascular endothelium (Devic et al., 1996 (Devic et al., , 1999 . Their endogenous ligand was identified later and called apelin (Tatemoto et al., 1998) . Apelin gene codes for a preproprotein of 77 amino acids, which can generate at least two active peptide fragments in vivo: apelin (42-77) and apelin (65-77). Apelin receptor genes are strongly expressed during the embryonic formation of blood vessels (Devic et al., 1999) and during the postnatal development of retinal vessels (Saint-Geniez et al., 2002) . Activation of apelin receptor leads to the inhibition of adenylyl cyclase and to the phosphorylation of extracellular signal-regulated kinase (ERK), Akt and p70 S6 kinase (Masri et al., 2004 . In agreement with the activation of these intracellular effectors, apelin (65-77) was shown to be a mitogen for the endothelial cell (Masri et al., 2004) and to display angiogenic properties in matrigel experiments (Kasai et al., 2004) . Taken together, these findings outline the physiological role of apelin signalling at the endothelial and vascular level (Masri et al., 2005; Audigier, 2006) .
Because neovascularization is a prerequisite for the development of solid tumours, we decided to characterize the role of apelin signalling in tumour neoangiogenesis. We report here for the first time that apelin overexpression by TS/A tumoral cell line increases the in vivo tumour growth, and that the apelin gene is induced by hypoxia and upregulated in human tumours.
Results
The apelin receptor is not expressed by TS/A mammary tumoral cells We first investigated whether the apelin receptor was expressed by TS/A tumoral cells at the mRNA level. No amplified fragment of the size expected for the apelin receptor was detected following reverse transcription (RT)-PCR ( Figure 1a ). In addition, the basal expression level of apelin receptor measured by real-time PCR gave a high cycle threshold (C t ) value (34.070.6).
To confirm the absence of the receptor protein at the surface of the TS/A tumoral cells, we analysed the ability of apelin (65-77) to regulate the activity of two intracellular effectors, adenylyl cyclase and ERK, as described in other cell types (Habata et al., 1999; Masri et al., 2002 Masri et al., , 2006 . As shown in Figure 1b , high concentrations of apelin (65-77) did not inhibit forskolinstimulated cAMP production by adenylyl cyclase. In addition, apelin (65-77) did not promote the phosphorylation of ERK, in contrast to epidermal growth factor (EGF) (Figure 1c ). Taken together, these data indicate that apelin receptor is not expressed by the TS/A tumour cell line.
Generation of stable TS/A clones overexpressing apelin
We first determined the basal expression level of apelin by real-time PCR and obtained a high C t value (33.071.9), which indicated that apelin gene was not expressed, or at least at very low levels, by TS/A tumoral cells. Therefore, we established and isolated mocktransfected (TS/A-mock) clones and apelin-transfected (TS/A-apelin) clones. The high expression levels of TS/A-apelin clones were confirmed by real-time PCR as we obtained a low C t value for most clones (C t ¼ 15.370.4).
Apelin overexpression does not alter the in vitro proliferation but accelerates the in vivo tumour growth We then analysed the in vitro proliferation rate of three TS/A-mock clones and three TS/A-apelin clones chosen for their high levels of apelin mRNA. As anticipated due to the absence of expression of the receptor, we did not observe significant differences in the in vitro proliferation rate between TS/A-mock and TS/A-apelin clones (Figure 2a) . Accordingly, apelin overexpression does not alter the in vitro proliferation of TS/A-apelin clones.
We then compared the in vivo growth rate of tumours following subcutaneous injection of these TS/A-mock and TS/A-apelin clones in mice (Figure 2b ). After only 11 days post-injection, the apelin tumours were clearly visible under the skin of mice while the control tumours remained undetectable. Cells from TS/A-mock clones generated detectable tumours later, but thereafter they grew as rapidly as apelin tumours. Analysis of the growth of all control tumours at later stages confirmed that the slopes of the growth curves were similar and revealed that the curve of the apelin tumours was shifted to the left, with a constant difference of 7 days for each time point (Figure 2b and data not shown). We also verified by RT-PCR that apelin overexpression was not lost after in vivo growth in apelin tumours derived from TS/A-apelin clones (data not shown).
Analysis of tumour vascularity in control and apelin tumours
The differential effect of apelin overexpression on in vitro cell proliferation and in vivo tumour growth is in agreement with the angiogenic activity of apelin and its putative effect on the angiogenic switch.
To assess tumour neoangiogenesis, we first analysed the expression levels of the endothelial marker CD31/ PECAM-1 in control and apelin tumours of the same size by real-time PCR. As shown in Figure 3a , we observed a slight but significant increase in CD31 expression from apelin tumours when compared to that of control tumours.
We also stained intratumoral vessels with CD31 antibodies and compared its expression pattern inside tumours of similar size ( Figure 3b ). As observed at the mRNA level, the amount of CD31 protein was 1.3-fold higher in apelin tumours than in control tumours. Interestingly, apelin overexpression was associated with the formation of large vessels lined with CD31-positive cells, whereas the control tumours contained a dense network made of small vessels. A quantification of the vascular surface areas stained by CD31 expression clearly confirmed that tumours overexpressing apelin contain fewer small vessels and more large vessels than control tumours (Figure 3c ).
Upregulation of apelin gene by gaseous hypoxia
One important property for a gene encoding an angiogenic factor is its ability to be induced by hypoxia, as hypoxic regions inside the tumour would initiate the angiogenic switch by secreting vasoactive peptides.
By real-time PCR, we found that apelin gene was strongly induced by hypoxia in TS/A cells at 8 h reaching a C t value of 28.473.4, and then its expression returned to basal levels at 24 h (Figure 4 ). The kinetics of this upregulation was very similar to that observed for VEGF-A gene, but the extent of this upregulation was twofold higher (Figure 4) . Consequently, these findings demonstrate that apelin gene is upregulated by gaseous hypoxia in a tumoral cell line.
Pathological relevance of apelin signalling in tumour neoangiogenesis
To address the pathological relevance of apelin signalling in tumour neovascularization, a cancer-profiling array containing 154 pairs of cDNAs from normal and tumour tissues of a same patient was analysed to determine the variations of apelin expression in human tumours (Figure 5a ).
Quantitative analysis with a 1.5-fold difference cutoff revealed no significant change in 89 samples, a decrease in 16 samples and an increase of apelin mRNAs in 49 samples out of 154 tumours ( Figure 5 , Table 1 ). Accordingly, a clear upregulation of apelin gene with a mean fold increase of 2.5270.20 occurs in one-third of the human tumours (Table 1) .
Interestingly, the tissue origin of the tumoral cells was important for its ability to upregulate apelin gene ( Figure 5b , Table 1 ). Clearly, tumours from liver and bladder, and vulva, stomach, rectum, uterus and testis to a lesser extent, do not frequently exhibit a significant increase of apelin gene expression. On the other hand, the frequency of apelin gene upregulation was very high in samples from colon, skin and pancreas (Table 1 ). In addition, the extent of the upregulation observed in pancreatic cancers reached a 3.5-fold mean increase of apelin expression (Table 1) .
Discussion
In this study, several results clearly rule out an autocrine effect of apelin overexpression on TS/A cells. First, no apelin receptor expression could be detected in these tumour cells (Figure 1) . Second, apelin overexpression did not increase the in vitro proliferation of the tumour cells (Figure 2a) . Third, apelin overexpression essentially accelerates in vivo the onset of tumour development rather than its growth rate (Figure 2b) . Finally, we observed the same effects with another tumoral cell line (Sorli et al., 2006) , suggesting that the effects of apelin overexpression are tumour-independent.
Accordingly, apelin overexpression would rather act on the vascular component of the tumour, by a paracrine action on the endothelial cells of the host vessels. Indeed, these findings are in good correlation with the mitogenic role of apelin on endothelial cells (Masri et al., 2004) and its angiogenic properties in matrigel experiments (Kasai et al., 2004) . This result is corroborated by a higher expression of the endothelial marker CD31 and the presence of large vessels in the tumours derived from TS/A-apelin clones (Figure 3) . Interestingly, such a finding has been already reported following overexpression of VEGF and FGF-2 (Graeven et al., 2001). Taken together, apelin would primarily accelerate the angiogenic switch and activate tumour neoangiogenesis, which in turn increases the in vivo growth of the tumour.
Another expected property for an angiogenic peptide is that its gene should be induced by hypoxia. We report here a strong increase of apelin expression induced by gaseous hypoxia, a property that may be correlated with the presence of several potential hypoxia responsive elements in the sequence of apelin gene. A recent publication also reported an increase of apelin gene expression induced by 'chemical hypoxia' in cardiac myocytes (Cox et al., 2006) . As the amplitude of the hypoxia-induced upregulation can vary from one cell type to another, it is noteworthy that the extent of apelin gene upregulation is higher than that of VEGF in TS/A tumoral cells. In addition, these results demonstrate that the hypoxia-induced upregulation observed in vitro should also participate in the neoangiogenesis of the tumours derived from the same TS/A-mock clones in vivo. Taken together, the faster onset of tumour growth is likely to depend on a critical threshold of apelin expression, which should be reached more early in apelin tumours. Accordingly, constitutive expression of apelin by TS/A-apelin clones would induce more rapidly the angiogenic switch and thus, allow early expansion of the tumours. On the other hand, control tumours need a delay to reach the same apelin levels by hypoxia-induced upregulation of apelin gene inside the tumour.
Evidently, the pathological relevance of this neoangiogenic activity is demonstrated by the high frequency of apelin gene upregulation observed in one-third of human tumours and in half of some digestive and skin cancers. In addition, the mean increase of apelin expression was particularly high (3.5-fold) in pancreatic cancers. The origin of apelin upregulation may depend on environmental conditions of the tumour cells such as hypoxia. However, activation of various oncogenes or inactivation of various tumour suppressor genes can also lead to the upregulation of genes encoding angiogenic factors (Rak et al., 1995; Brugarolas and Kaelin, 2004) . Accordingly, both genetic factors and environmental cues can ultimately contribute to the upregulation of the apelin gene detected in human tumours. Indeed, inactivating mutations affecting the von Hippel-Lindau gene in various tumours are associated with a general increased expression of all the hypoxia-regulated angiogenic factors (Lonser et al., 2003) . Regardless of its origin, the high frequency of this upregulation suggests that apelin can be considered as a major angiogenic peptide that stimulates the formation of tumoral vessels.
As the growth of solid tumours is dependent on the formation of a neovascular supply, inhibition of tumour-induced neoangiogenesis represents an effective strategy to treat human cancers (Folkman, 1971) . Indeed, inactivation of VEGF-A signalling decreases tumour growth in vivo (Kim et al., 1993; Millauer et al., 1994; Prewett et al., 1999; Wood et al., 2000; Holash et al., 2002) , and the administration of an antibody against VEGF-A (bevacizumab) in combination with an antitumoral agent provides a survival benefit to patients bearing metastatic colorectal cancers (Hurwitz et al., 2004) . However, a tumour can secrete various angiogenic peptides either at the beginning of tumour development or as a result of its 'vascular resistance' to an antiangiogenic chemotherapy. It is tempting to speculate that a mixture of anti-VEGF approaches with an antagonist of the apelin receptor should strongly improve the efficacy of the therapeutic strategies used to fight against the growth of solid tumours.
Materials and methods
Cell culture and transfection TS/A mammary carcinoma cells were cultured in RPMI 1640 medium supplemented with 2 mM L-glutamine and 10% fetal calf serum (FCS). TS/A-mock and TS/A-apelin clones were obtained by transfection of pREN or pREN-apelin plasmids using jetPEI transfection (Qbiogene, Eury, France). The cDNA encoding the murine apelin gene corresponds to the coding region flanked by 100 and 23 nucleotides of 5 0 -and 3 0 -untranslated regions, respectively (Saint-Geniez et al., 2002) . Stable transfectants were selected by their resistance to geneticin (0.5 mg/ml). Ten TS/A-mock and ten TS/A-apelin clones were isolated and expression of apelin was determined by RT-PCR.
Reverse transcription, PCR and real-time PCR Total RNA was extracted with TriReagent (Molecular Research Center, Euromedex, Mundelsheim, France), and 2 mg was reverse transcribed using Superscript III (Invitrogen, Cergy-Pontoise, France). Primers used for PCR were 5 0 -atgaatctgaggctctgcgtgcagg and 5 0 -gaaaggcatggggcccttatgg for mouse apelin-receptor and 5 0 -tcacgccatcctgcgtctggact and 5 0 -ccggactcatcgtactcct for s-actine. Real-time PCR was carried out using 50 ng of cDNA with an ABI Prism 7900HT detection system. Apelin, apelin receptor and CD31 probes were purchased from Applied Biosystems (Courtaboeuf, France) as TaqMan Gene Expression Assay-On-Demand and combined with TaqMan Universal PCR Master Mix. 18S cDNA was used as a normalization control with the primers 5 0 -caactaagaacggccatgca and 5 0 -agcctgcggcttaatttgac and the SYBR Green JumpStart Taq ReadyMix (Sigma, Saint Quentin-Fallavier, France). The relative gene expression was analysed using the 2 ÀDDCT method (Livak and Schmittgen, 2001) .
Adenylyl cyclase assay TS/A cells were seeded onto six-well plates (3 Â 10 4 cells/well). Forty-eight hours later, the cells were washed twice with phosphate-buffered saline (PBS) and then incubated for 15 min at 371C in 1 ml RPMI 1640 medium containing 20 mM forskolin and 0.5 mM 3-isobutyl-1-methylxanthine in the presence or absence of 10 À6 M apelin (65-77) (Bachem, Voisins Le Bretonneux, France). The amount of cAMP was determined on cell lysates by radioimmunoassay in monoclonal antibody-coated tubes in the presence of 125 I-labelled tracer (Immunotech, Beckman Coulter, Roissy, CDG, France) as described by Masri et al. (2004 Masri et al. ( , 2006 . The extents of this upregulation observed in the various pairs of the same tissue were pooled and the mean fold7s.e.m. was calculated.
Apelin and tumour neoangiogenesis SC Sorli et al
Immunoblotting TS/A cells (5 Â 10 5 ) were seeded onto 10 cm culture dishes. After twenty-four hours, cells were serum starved in RPMI 1640 medium containing 0.4% bovine serum albumin (BSA) for 16 h, and then stimulated for 5 min with 10 À6 M apelin (65-77) and 10 min with 20 ng/ml EGF or not stimulated. Cells were then lysed as described by Masri et al. (2004 Masri et al. ( , 2006 . Fifty microgram of proteins from cell lysates were fractionated on 12% sodium dodecyl sulfate-polyacrylamide gels and blotted to Protan nitrocellulose membranes (Schleider and Shuell, Dassel, Germany). Immunoblotting was performed using antiphospho p44/42 MAPK (E10; Cell Signaling, Ozyme, St Quentin Yvelines, France) and anti-ERK2 (C-14; Santa Cruz Biotechnologies, Heidelberg, Germany) antibodies as described before .
MTT proliferation assay
TS/A-mock and TS/A-apelin cells were seeded onto 24-well plates (5000 cells/well). At the indicated time, the medium was replaced by 500 ml/well of culture medium containing 0.5 mg/ ml thiazol blue tetrazolium bromide (MTT) solution (Sigma) and cells were incubated at 371C for 1 h. The medium was removed, MTT-formazan crystals were dissolved in 500 ml of dimethylsulfoxide and colour intensities were measured at 570 nm.
Tumour model
Animal experiments were conducted in accordance with the 86/609/EC European directive, and our protocol was approved by the Regional Ethics Committee of Midi-Pyre´ne´es for Animal Experimentation. A total of 2.5 Â 10 5 TS/A cells of a TS/A-mock or TS/A-apelin clone were injected subcutaneously into the flank of 5-week old female BALB/c syngeneic mice (Janvier, Le Genest, St Isle, France). Mice body weight and tumour volume were measured three times a week using the formula length Â width 2 Â p/6. Tumours derived from TS/ A-mock clones (control tumours) or from TS/A-apelin clones (apelin tumours) were removed after 22-29 days post-injection. For RNA extraction, tumours were snap frozen in liquid nitrogen. For histological analyses, tumours were embedded in O.C.T. compound (Sakura, Zoeterwoude, The Netherlands) before being frozen in liquid nitrogen-cooled isopentane.
Immunohistochemistry
Ten micrometre frozen sections from TS/A tumours were postfixed in 4% paraformaldehyde for 5 min at room temperature. Sections were blocked in PBS/0.2% BSA/10% FCS, and incubated overnight at 41C with anti-CD31 antibody (BD Pharmingen, Le Pont de Claix, France) diluted 1:50. Samples were then washed three times in PBS/0.2% BSA/0.02% Tween 20 and incubated for 10 min at room temperature in peroxidase-blocking reagent (RTU, Dako, Trappes, France). Sections were then incubated for 30 min with the secondary biotinylated anti-rat IgG antibody (Vector Laboratories, Clinisciences, Montrouge, France) diluted 1:200. After washing, a horseradish peroxidase (HRP)-streptavidin solution (RTU, Dako) was incubated on samples for 20 min and the protein location revealed using the HRP kit DAB liquid substrate (Dako).
Quantification of vessel areas
Images of the whole sections were reconstructed from photographs taken with a Â 4 objective using a Nikon Eclipse E400 light microscope and a Sony DXC 950 camera using Mosaic Image software (Explora Nova). Quantitative data of the CD31 staining were obtained using Morpho Expert 2.5 software (Explora Nova).
Gaseous hypoxia TS/A-mock cells were seeded at a density of 2.5 Â 10 4 cells/cm 2 for 24 h and then placed in a humidified 1% O 2 , 5% CO 2 incubator at 371C for 8-48 h. At the indicated time, cells were scrapped on ice in cold PBS and centrifuged at 1200 g for 5 min at 41C. Cell pellets were stored at À201C before RNA extraction.
Cancer-profiling array
The Cancer Profiling Array II (BD Biosciences, Clontech, St Quentin Yvelines, France) was hybridized with 20 ng of a 1.5 kb apelin probe labelled with [a 32 P]-dCTP (10 9 cpm/mg) using Megaprime DNA labelling system (GE Healthcare, Orsay, France). The DNA matrix for the probe preparation was generated by PCR using the human apelin cDNA clone MGC:31846 (GeneService, Cambridge, UK) and the primers 5 0 -atgaatctgcggctctgcgtgcagg and 5 0 -tggagtccagtgattgaaggc. The membrane was then stripped and hybridized with a 32 Plabelled ubiquitin probe for normalization. The membrane was exposed to an intensifying screen and then developed using a Typhoon 9400 machine (Amersham Biosciences, Orsay, France). Spot intensities were quantified using ImaGene 5.0 software (Biodiscovery) and each apelin signal was normalized to the corresponding ubiquitin signal. The ratios of standardized apelin signals in tumour tissue versus normal tissue were calculated within each pair and expressed as fold increase or decrease. Changes were considered significant above a 1.5-fold difference (cutoff).
Statistical analyses
Data are expressed as the mean7s.e.m.. Statistical analyses were performed using the t-test or two-way analysis of variance followed by the Bonferroni test using GraphPad Prism 4 software (GraphPad Software). P-values less than 0.05 (*), 0.01 (**) or 0.001 (***) were considered statistically significant.
